CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation an… Read more
CONMED Corporation (CNMD) - Net Assets
Latest net assets as of December 2025: $1.03 Billion USD
Based on the latest financial reports, CONMED Corporation (CNMD) has net assets worth $1.03 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.33 Billion) and total liabilities ($1.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.03 Billion |
| % of Total Assets | 44.42% |
| Annual Growth Rate | 15.38% |
| 5-Year Change | 31.53% |
| 10-Year Change | 77.94% |
| Growth Volatility | 39.32 |
CONMED Corporation - Net Assets Trend (1986–2025)
This chart illustrates how CONMED Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CONMED Corporation (1986–2025)
The table below shows the annual net assets of CONMED Corporation from 1986 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.03 Billion | +7.31% |
| 2024-12-31 | $962.68 Million | +15.40% |
| 2023-12-31 | $834.22 Million | +11.89% |
| 2022-12-31 | $745.54 Million | -5.08% |
| 2021-12-31 | $785.43 Million | +10.77% |
| 2020-12-31 | $709.04 Million | -0.20% |
| 2019-12-31 | $710.47 Million | +7.28% |
| 2018-12-31 | $662.27 Million | +4.88% |
| 2017-12-31 | $631.43 Million | +8.76% |
| 2016-12-31 | $580.58 Million | -0.77% |
| 2015-12-31 | $585.07 Million | +0.65% |
| 2014-12-31 | $581.30 Million | -4.13% |
| 2013-12-31 | $606.32 Million | -0.11% |
| 2012-12-31 | $607.00 Million | +5.92% |
| 2011-12-31 | $573.07 Million | -2.30% |
| 2010-12-31 | $586.56 Million | +1.74% |
| 2009-12-31 | $576.51 Million | +8.42% |
| 2008-12-31 | $531.73 Million | +5.29% |
| 2007-12-31 | $505.00 Million | +14.68% |
| 2006-12-31 | $440.35 Million | -2.79% |
| 2005-12-31 | $453.01 Million | +1.12% |
| 2004-12-31 | $447.98 Million | +3.34% |
| 2003-12-31 | $433.49 Million | +12.03% |
| 2002-12-31 | $386.94 Million | +36.42% |
| 2001-12-31 | $283.63 Million | +23.00% |
| 2000-12-31 | $230.60 Million | +9.14% |
| 1999-12-31 | $211.30 Million | +15.97% |
| 1998-12-31 | $182.20 Million | +11.99% |
| 1997-12-31 | $162.70 Million | +2.59% |
| 1996-12-31 | $158.60 Million | +111.47% |
| 1995-12-31 | $75.00 Million | +74.01% |
| 1994-12-31 | $43.10 Million | +14.93% |
| 1993-12-31 | $37.50 Million | -3.10% |
| 1992-12-31 | $38.70 Million | +13.82% |
| 1991-12-31 | $34.00 Million | +165.63% |
| 1990-12-31 | $12.80 Million | +24.27% |
| 1989-12-31 | $10.30 Million | -5.50% |
| 1988-12-31 | $10.90 Million | +7.92% |
| 1987-12-31 | $10.10 Million | +158.97% |
| 1986-12-31 | $3.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CONMED Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15812.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $588.77 Million | 56.99% |
| Common Stock | $313.00K | 0.03% |
| Other Comprehensive Income | $-46.30 Million | -4.48% |
| Other Components | $490.31 Million | 47.46% |
| Total Equity | $1.03 Billion | 100.00% |
CONMED Corporation Competitors by Market Cap
The table below lists competitors of CONMED Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guosheng Financial Holding Inc
SHE:002670
|
$1.14 Billion |
|
Hyulim ROBOT Co.Ltd
KQ:090710
|
$1.14 Billion |
|
Dorchester Minerals LP
NASDAQ:DMLP
|
$1.14 Billion |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
$1.14 Billion |
|
Guizhou Aviation Technical Development Co Ltd
SHG:688239
|
$1.14 Billion |
|
MRC Global Inc
NYSE:MRC
|
$1.14 Billion |
|
Weimob Inc
PINK:WEMXF
|
$1.14 Billion |
|
Shanghai Moons' Elec Co Ltd
SHG:603728
|
$1.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CONMED Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 962,681,000 to 1,033,097,000, a change of 70,416,000 (7.3%).
- Net income of 47,055,000 contributed positively to equity growth.
- Dividend payments of 24,746,000 reduced retained earnings.
- Other comprehensive income increased equity by 12,562,000.
- Other factors increased equity by 35,545,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $47.05 Million | +4.55% |
| Dividends Paid | $24.75 Million | -2.4% |
| Other Comprehensive Income | $12.56 Million | +1.22% |
| Other Changes | $35.55 Million | +3.44% |
| Total Change | $- | 7.31% |
Book Value vs Market Value Analysis
This analysis compares CONMED Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 66.99x to 1.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-12-31 | $0.56 | $37.34 | x |
| 1987-12-31 | $1.29 | $37.34 | x |
| 1988-12-31 | $1.09 | $37.34 | x |
| 1989-12-31 | $0.92 | $37.34 | x |
| 1990-12-31 | $1.32 | $37.34 | x |
| 1991-12-31 | $2.67 | $37.34 | x |
| 1992-12-31 | $2.64 | $37.34 | x |
| 1993-12-31 | $2.86 | $37.34 | x |
| 1995-12-31 | $4.31 | $37.34 | x |
| 1996-12-31 | $7.27 | $37.34 | x |
| 1997-12-31 | $7.18 | $37.34 | x |
| 1998-12-31 | $7.92 | $37.34 | x |
| 1999-12-31 | $9.12 | $37.34 | x |
| 2000-12-31 | $9.91 | $37.34 | x |
| 2001-12-31 | $11.62 | $37.34 | x |
| 2002-12-31 | $13.94 | $37.34 | x |
| 2003-12-31 | $14.86 | $37.34 | x |
| 2004-12-31 | $14.86 | $37.34 | x |
| 2005-12-31 | $15.29 | $37.34 | x |
| 2006-12-31 | $15.84 | $37.34 | x |
| 2007-12-31 | $17.42 | $37.34 | x |
| 2008-12-31 | $18.19 | $37.34 | x |
| 2009-12-31 | $19.78 | $37.34 | x |
| 2010-12-31 | $20.29 | $37.34 | x |
| 2011-12-31 | $20.01 | $37.34 | x |
| 2012-12-31 | $21.18 | $37.34 | x |
| 2013-12-31 | $21.57 | $37.34 | x |
| 2014-12-31 | $20.93 | $37.34 | x |
| 2015-12-31 | $21.00 | $37.34 | x |
| 2016-12-31 | $20.76 | $37.34 | x |
| 2017-12-31 | $22.41 | $37.34 | x |
| 2018-12-31 | $22.92 | $37.34 | x |
| 2019-12-31 | $24.09 | $37.34 | x |
| 2020-12-31 | $24.06 | $37.34 | x |
| 2021-12-31 | $24.38 | $37.34 | x |
| 2022-12-31 | $24.82 | $37.34 | x |
| 2023-12-31 | $26.44 | $37.34 | x |
| 2024-12-31 | $30.94 | $37.34 | x |
| 2025-12-31 | $33.17 | $37.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CONMED Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.42%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 2.25x
- Recent ROE (4.55%) is below the historical average (6.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | 17.95% | 6.67% | 1.64x | 1.64x | $310.00K |
| 1987 | 10.89% | 8.80% | 0.96x | 1.29x | $90.00K |
| 1988 | 7.34% | 5.63% | 1.05x | 1.24x | $-290.00K |
| 1989 | -2.91% | -1.51% | 0.91x | 2.13x | $-1.33 Million |
| 1990 | 18.75% | 7.64% | 1.41x | 1.73x | $1.12 Million |
| 1991 | 11.47% | 10.13% | 1.01x | 1.13x | $500.00K |
| 1992 | 10.59% | 9.62% | 1.02x | 1.08x | $230.00K |
| 1993 | -3.73% | -2.61% | 0.94x | 1.53x | $-5.15 Million |
| 1995 | 14.53% | 10.94% | 0.83x | 1.59x | $3.40 Million |
| 1996 | 10.28% | 12.98% | 0.74x | 1.07x | $440.00K |
| 1997 | -4.36% | -5.13% | 0.25x | 3.45x | $-23.37 Million |
| 1998 | 9.77% | 5.29% | 0.53x | 3.45x | $-420.00K |
| 1999 | 12.87% | 7.30% | 0.56x | 3.13x | $6.07 Million |
| 2000 | 8.38% | 4.92% | 0.58x | 2.95x | $-3.75 Million |
| 2001 | 8.60% | 5.69% | 0.61x | 2.47x | $-3.96 Million |
| 2002 | 8.83% | 7.54% | 0.61x | 1.92x | $-4.54 Million |
| 2003 | 7.40% | 6.45% | 0.62x | 1.86x | $-11.27 Million |
| 2004 | 7.47% | 5.99% | 0.64x | 1.95x | $-11.33 Million |
| 2005 | 7.06% | 5.18% | 0.68x | 2.00x | $-13.31 Million |
| 2006 | -2.84% | -1.93% | 0.75x | 1.96x | $-56.54 Million |
| 2007 | 8.21% | 5.97% | 0.78x | 1.77x | $-9.04 Million |
| 2008 | 8.38% | 6.00% | 0.80x | 1.75x | $-8.61 Million |
| 2009 | 2.11% | 1.75% | 0.73x | 1.66x | $-45.51 Million |
| 2010 | 5.17% | 4.25% | 0.72x | 1.68x | $-28.31 Million |
| 2011 | 0.13% | 0.10% | 0.77x | 1.63x | $-56.56 Million |
| 2012 | 6.67% | 5.28% | 0.71x | 1.79x | $-20.22 Million |
| 2013 | 5.93% | 4.75% | 0.69x | 1.80x | $-24.69 Million |
| 2014 | 5.54% | 4.38% | 0.67x | 1.89x | $-25.94 Million |
| 2015 | 5.21% | 4.24% | 0.65x | 1.90x | $-28.01 Million |
| 2016 | 2.53% | 1.92% | 0.57x | 2.29x | $-43.39 Million |
| 2017 | 8.79% | 6.97% | 0.59x | 2.15x | $-7.66 Million |
| 2018 | 6.17% | 4.75% | 0.63x | 2.07x | $-25.37 Million |
| 2019 | 4.03% | 3.00% | 0.54x | 2.50x | $-42.43 Million |
| 2020 | 1.34% | 1.10% | 0.49x | 2.47x | $-61.39 Million |
| 2021 | 7.96% | 6.19% | 0.57x | 2.25x | $-16.00 Million |
| 2022 | -10.81% | -7.71% | 0.46x | 3.08x | $-155.14 Million |
| 2023 | 7.73% | 5.18% | 0.54x | 2.76x | $-18.96 Million |
| 2024 | 13.76% | 10.13% | 0.57x | 2.40x | $36.15 Million |
| 2025 | 4.55% | 3.42% | 0.59x | 2.25x | $-56.25 Million |
Industry Comparison
This section compares CONMED Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CONMED Corporation (CNMD) | $1.03 Billion | 17.95% | 1.25x | $1.14 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |